Terms: = Pancreatic cancer AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP AND Clinical Outcome
4 results:
1. clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in brca1 and BRCA2 genes.
Militello AM; Orsi G; Cavaliere A; Niger M; Avallone A; Salvatore L; Tortora G; Rapposelli IG; Giordano G; Noventa S; Giommoni E; Bozzarelli S; Macchini M; Peretti U; Procaccio L; Puccini A; Cascinu S; Montagna C; Milella M; Reni M
Cancer Chemother Pharmacol; 2023 Dec; 92(6):501-510. PubMed ID: 37725113
[TBL] [Abstract] [Full Text] [Related]
2. Improving Gemcitabine Sensitivity in pancreatic cancer Cells by Restoring miRNA-217 Levels.
Panebianco C; Trivieri N; Villani A; Terracciano F; Latiano TP; Potenza A; Perri F; Binda E; Pazienza V
Biomolecules; 2021 Apr; 11(5):. PubMed ID: 33925948
[TBL] [Abstract] [Full Text] [Related]
3. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.
Villarroel MC; Rajeshkumar NV; Garrido-Laguna I; De Jesus-Acosta A; Jones S; Maitra A; Hruban RH; Eshleman JR; Klein A; Laheru D; Donehower R; Hidalgo M
Mol Cancer Ther; 2011 Jan; 10(1):3-8. PubMed ID: 21135251
[TBL] [Abstract] [Full Text] [Related]
4. Down-regulation of brca1 in chronic pancreatitis and sporadic pancreatic adenocarcinoma.
Beger C; Ramadani M; Meyer S; Leder G; Krüger M; Welte K; Gansauge F; Beger HG
Clin Cancer Res; 2004 Jun; 10(11):3780-7. PubMed ID: 15173085
[TBL] [Abstract] [Full Text] [Related]
